Research Topics
Genomes and GenesSpecies | D J SlamonSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Advances in adjuvant therapy for breast cancerDennis J Slamon
Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, USA
Clin Adv Hematol Oncol 4:suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10. 2006..Finally, new targeted agents are being investigated and ongoing research aims to identify additional potential therapeutic targets to further improve outcomes for these patients...
Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot studyCarolyn D Britten
Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Santa Monica, CA 90404 2429, USA
BMC Cancer 12:16. 2012..This pilot study examined whether intravenous (IV) bevacizumab, a monoclonal antibody against VEGF, could inhibit neovessel formation after TACE...- Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancerYanyuan Wu
Divisions of Cancer Research and Training, Hematology Oncology, Department of Medicine, Charles R Drew University of Medicine and Science, 1731 East 120th Street, Los Angeles, CA 90059, USA
Breast Cancer Res 10:R3. 2008..Cellular and molecular studies have shown that activation of the cell signaling phosphatidylinositol-3-kinase/Akt cascade via the HER2/neu and other receptor tyrosine kinases induces cell proliferation... - PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroRichard S Finn
Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11 934 Factor Bldg, Los Angeles, CA 90095, USA
Breast Cancer Res 11:R77. 2009..To identify predictors of response, we determined the in vitro sensitivity to PD 0332991 across a panel of molecularly characterized human breast cancer cell lines... - HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cellsCindy A Wilson
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Breast Cancer Res 7:R1058-79. 2005.... - Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylationYanyuan Wu
Division of Cancer Research and Training, Department of Internal Medicine, Charles R, Drew University of Medicine and Science, Los Angeles, CA 90059, USA
BMC Cancer 10:32. 2010..Epigenetic changes associated with promoter DNA methylation results in silencing of several tumor suppressor genes that lead to increased risk for tumor formation and for progression of the cancer... - Adjuvant trastuzumab in HER2-positive breast cancerDennis Slamon
Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095 1678, USA
N Engl J Med 365:1273-83. 2011..We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab... - Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2D J Slamon
Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, Calif 90095 1678, USA
N Engl J Med 344:783-92. 2001..The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor... - Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancerGottfried E Konecny
Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, and Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095-7077, USA
J Natl Cancer Inst 96:1141-51. 2004..Furthermore, a taxane-containing regimen such as ET may provide a preferential benefit to patients with HER-2/neu-positive tumors... 
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinibNeil A O'Brien
Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 7077, USA
Mol Cancer Ther 9:1489-502. 2010..In conclusion, pharmacologic targeting of the PI3K/AKT pathway may provide benefit to HER2-positive breast cancer patients who are resistant to trastuzumab therapy...- A candidate tumor suppressor gene, H37, from the human lung cancer tumor suppressor locus 3p21.3Juliana J Oh
Department of Medicine, University of California, Los Angeles, CA 90095, USA
Cancer Res 62:3207-13. 2002..H37 also suppressed anchorage-dependent and -independent growth of A9 mouse fibrosarcoma cells and inhibited tumor formation in nude mice. These data indicate a potential role for H37 as one of the 3p TSGs in human lung cancer... - EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cellsJoshua A Bryant
Department of Neurology David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California90095, USA
Cancer Biol Ther 3:1243-9. 2004..Distinct intra- and intercellular Ca2+ signaling pathways may be mechanisms by which EGF modulates the growth and migration of tumor cells... - Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimensMichael F Press
Breast Cancer Research Program of the Lee Breast Center, Department of Pathology, University of Southern California, Los Angeles, USA
J Clin Oncol 20:3095-105. 2002..To compare and evaluate HER-2/neu clinical assay methods... - HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomasM F Press
Norris Comprehensive Cancer Center and Department of Pathology, University of Southern California School of Medicine, Los Angeles, CA 90033, USA
J Clin Oncol 15:2894-904. 1997.... - Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatmentM D Pegram
Department of Medical Oncology, The University of California at Los Angeles, USA
J Clin Oncol 16:2659-71. 1998..v.) administration of recombinant, humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) plus cisplatin (CDDP) in a phase II, open-label, multicenter clinical trial for patients with HER2/neu-overexpressing metastatic breast cancer... - Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell linesEdward B Garon
1Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, California, USA
Mol Cancer Ther 9:1985-94. 2010..In total, these results suggest that clinical trials of selumetinib in breast cancer and NSCLC might select patients whose tumors harbor raf and ras mutations, respectively... - Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitroRichard S Finn
Department of Medicine, Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11 934 Factor Bldg, Los Angeles, CA 90095, USA
Breast Cancer Res Treat 105:319-26. 2007..e. hormonal manipulation or trastuzumab)... - The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptorsDennis J Slamon
Division of Hematology-Oncology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, 90095-7077, USA
Oncologist 9:1-3. 2004 - Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridizationWilliam D Tap
Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
Genes Chromosomes Cancer 50:95-112. 2011..This detailed genetic mapping provides insight into the heterogeneity of WD and DDLS and the chromosomal and genetic abnormalities that are present in and distinguish these mesenchymal malignancies... - 3p21.3 tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosisJuliana J Oh
Division of Hematology Oncology, University of California at Los Angeles School of Medicine, 675 Charles E Young Drive South, Los Angeles, CA 90095, USA
Cancer Res 66:3419-27. 2006..Lastly, we proposed a tumor suppression model of H37 as a post-transcriptional regulator for cell cycle/apoptotic-related proteins... - Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification targetMarlena S Fejzo
Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA
Genes Chromosomes Cancer 47:873-83. 2008..Functional analysis is now warranted to determine whether ADRM1 is a target for early screening and/or therapy for ovarian cancer... - Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cellsGottfried E Konecny
Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, 12 145 Factor Building, 10945 Le Conte Avenue, Los Angeles, CA 90095 1678, USA
Cancer Res 66:1630-9. 2006..These observations provide a clear biological rationale to test lapatinib as a single agent or in combination with trastuzumab in HER-2-overexpressing breast cancer and in patients with clinical resistance to trastuzumab... - The two single nucleotide polymorphisms in the H37/RBM5 tumour suppressor gene at 3p21.3 correlated with different subtypes of non-small cell lung cancersJuliana J Oh
Division of Hematology Oncology, University of California at Los Angeles School of Medicine, 11 934 Factor Building, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
Lung Cancer 58:7-14. 2007..In addition, because of prevalent loss of heterozygosity (LOH) detected at 3p21.3 which precedes lung cancer initiation, these SNPs may be developed into a marker screening for the high risk individuals... - Promoter methylation study of the H37/RBM5 tumor suppressor gene from the 3p21.3 human lung cancer tumor suppressor locusJuliana J Oh
Division of Hematology Oncology, School of Medicine, University of California at Los Angeles, 11 934 Factor Building, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
Hum Genet 123:55-64. 2008.... - RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasisJuliana J Oh
Division of Hematology Oncology, University of California at Los Angeles School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
Lung Cancer 70:253-62. 2010..Further study is warranted to evaluate the potential clinical utility of RBM5 in lung cancer diagnostics, prognostics and therapeutics... - Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivoZev A Wainberg
Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, California 90404, USA
Clin Cancer Res 16:1509-19. 2010.... - Periostin promotes ovarian cancer angiogenesis and metastasisMin Zhu
Division of Hematology Oncology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
Gynecol Oncol 119:337-44. 2010..In the present study, we investigated PN expression status in a large cohort of ovarian tumors with the focus on biological influence of PN related on ovarian tumor angiogenesis and metastasis... - Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancerGottfried E Konecny
UCLA Translational Oncology Research Lab, David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, 90404 2429, USA
Breast Cancer Res Treat 120:481-9. 2010..However, added benefit of IDD chemotherapy itself was not associated with HER2 or TOP2A status... - Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanomaWilliam D Tap
Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
Neoplasia 12:637-49. 2010..We sought to investigate the efficacy of PLX4032 (BRAF inhibitor) to identify patterns/predictors of response/resistance and to study the effects of BRAF in melanoma... - A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approachCarolyn D Britten
Department of Medicine, University of California, Los Angeles, CA, USA
Clin Breast Cancer 9:16-22. 2009..This phase I/II trial was conducted to determine the toxicities, recommended dose, pharmacokinetics, and response rate of erlotinib plus trastuzumab in metastatic HER2+ breast cancer... - Tissue microarrays from frozen tissues-OCT techniqueMarlena Schoenberg Fejzo
Division of Hematology Oncology, Department of Medicine, School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
Methods Mol Biol 664:73-80. 2010.... - A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01)Sara A Hurvitz
David Geffen School of Medicine, University of California, Los Angeles, CA, USA
Clin Breast Cancer 10:307-12. 2010..To assess the activity of docetaxel plus bevacizumab, a multicenter phase II trial was conducted... - Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trialsMichael F Press
Women's Cancers Program, Department of Pathology, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA 89195, USA
Clin Cancer Res 11:6598-607. 2005.... - Use of low-melting-point primers for bisulfite genomic sequencing: analysis of the H37 lung cancer tumor suppressor gene promoterJuliana J Oh
Hematology/Oncology Division, UCLA School of Medicine, Los Angeles, CA 90095, USA
Anal Biochem 343:347-9. 2005 - Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cellsM Jane Arboleda
Department of Medicine, Division of Hematology and Oncology, University of California Los Angeles, UCLA School of Medicine, Los Angeles, California 90095, USA
Cancer Res 63:196-206. 2003..Taken together, these data indicate that AKT2 mediates PI3-K-dependent effects on adhesion, motility, invasion, and metastasis in vivo... - Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recoveryRonald L Paquette
Department of Medicine, Division of Hematology Oncology, 42 121 UCLA Center for the Health Sciences, 10833 Le Conte Avenue, Los Angeles, CA 90095 1678, USA
Exp Hematol 30:374-80. 2002..The aim of this study was to evaluate the effect of various ex vivo expansion conditions on the cell products and their ability to accelerate hematopoietic recovery in patients undergoing stem cell transplantation... - Monoclonal antibody therapy for breast cancer: herceptinRichard S Finn
Geffen School of Medicine, UCLA, Department of Medicine, Los Angeles, CA 90095, USA
Cancer Chemother Biol Response Modif 21:223-33. 2003 - Evaluation of H37, a candidate 3p21.3 tumor suppressor gene, as a therapeutic and diagnostic marker in lung cancerJuliana J Oh
Division of Hematology/Oncology, UCLA School of Medicine, Los Angeles, CA, USA
Chest 125:102S-3S. 2004 - Activity of the multikinase inhibitor dasatinib against ovarian cancer cellsG E Konecny
Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90404 2429, USA
Br J Cancer 101:1699-708. 2009.... - A model-based approach for assessing in vivo combination therapy interactionsA M Lopez
Department of Biomathematics, School of Medicine, University of California, Los Angeles, CA 90095 1766, USA
Proc Natl Acad Sci U S A 96:13023-8. 1999.... - Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patientsGottfried E Konecny
Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1678, USA
Clin Cancer Res 10:1706-16. 2004..compare the prognostic significance of VEGF isoforms; and (c). analyze the combined effects of HER-2/neu and VEGF on clinical outcome... - Expression of c-Fes protein isoforms correlates with differentiation in myeloid leukemiasAnne Carlson
Division of Hematology-Oncology, Department of Medicine and Jonsson Comprehensive Cancer Center, UCLA School of Medicine, Los Angeles, California, USA
DNA Cell Biol 24:311-6. 2005..We infer that alternative splicing generates a family of c-Fes proteins. This may be a mechanism to direct the c-Fes kinase domain to different subcellular locations and/or substrates at specific stages of myeloid cell differentiation... - Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinideC P Reynolds
Division of Hematology Oncology, Childrens Hospital Los Angeles, Los Angeles, California 90027, USA
Med Pediatr Oncol 35:597-602. 2000..High-dose, pulse-13-cis-retinoic acid (13-cis-RA) given after intensive cytotoxic therapy improves event-free survival for high-risk neuroblastoma (NB), but more than 50% of patients have tumor recurrence... - Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancerR L Paquette
Departments of Medicine and Biostatistics, University of California at Los Angeles, Los Angeles, CA, USA
Blood 96:2385-90. 2000..Therefore, ex vivo expanded PBPC are capable of ameliorating posttransplantation neutropenia, thrombocytopenia, and anemia in patients receiving high-dose chemotherapy... - The transmembrane heregulin precursor is functionally activeZ Aguilar
Department of Medicine, Division of Hematology/Oncology, UCLA School of Medicine, Los Angeles, California 90024, USA
J Biol Chem 276:44099-107. 2001..This study demonstrates that transmembrane heregulin is functionally active and suggest it is capable of playing a role in cell-cell communication and subsequent signal transduction in vivo... - Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteinsM Schoenberg Fejzo
Division of Hematology Oncology, Department of Medicine, University of California, Los Angeles, School of Medicine, Los Angeles, California, USA
Am J Pathol 159:1645-50. 2001..We show OCT arrays work well for DNA, RNA, and protein analyses, and may have significant advantages over the original technology for the assessment of some genes and proteins by improving both qualitative and quantitative results... - Spatial and temporal changes in the subcellular localization of the nuclear protein-tyrosine kinase, c-FesAnne Carlson
Division of Hematology-Oncology, Department of Medicine, UCLA School of Medicine and Jonsson Comprehensive Cancer Center, Los Angeles, California, USA
DNA Cell Biol 24:225-34. 2005..The timing of c-Fes' appearance at the centromere coincides with the period of kinetochore assembly. These data suggest that c-Fes is recruited to the kinetochore during mitosis... - Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomasC A Wilson
Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095, USA
Nat Genet 21:236-40. 1999..Conversely, BRCA1 expression was reduced or undetectable in the majority of high-grade, ductal carcinomas, suggesting that absence of BRCA1 may contribute to the pathogenesis of a significant percentage of sporadic breast cancers... - Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cellsJ J Oh
Department of Medicine, Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, CA 90095 1678, USA
Nucleic Acids Res 27:4008-17. 1999..Further characterization of these genes may yield insight into the fundamental biology and pathogenetic effects of HER-2/ neu overexpression in human breast and ovarian cancer cells... - Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancerDavid Osoba
Quality of Life Consulting, West Vancouver, British Columbia, Canada
J Clin Oncol 20:3106-13. 2002.... - Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumorsAli Namazie
Division of Head and Neck Surgery, University of California Los Angeles School of Medicine, USA
Laryngoscope 112:472-81. 2002..Our results suggest that these two genetic aberrations together portend a poorer outcome than either of the abnormalities alone in head and neck cancer... - HER2 testing and correlation with efficacy of trastuzumab therapyGottfried Konecny
Oncology (Williston Park) 16:1576, 1578. 2002 - Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerCharles L Vogel
University of Miami School of Medicine, Comprehensive Cancer Research Group Inc, and Columbia Cancer Research Network of Florida, Miami, FL, USA
J Clin Oncol 20:719-26. 2002..CONCLUSION: Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH... - Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancerGottfried Konecny
Division of Hematology Oncology, Department of Medicine, and Jonsson Comprehensive Cancer Center, University of California at Los Angeles School of Medicine, Los Angeles 90095 1678, USA
J Natl Cancer Inst 95:142-53. 2003..To better understand the relationship between HER-2/neu positivity and HR expression, we analyzed HER-2/neu, ER, and PR as continuous variables in breast cancer cell lines and two cohorts of primary breast cancer patients... - Evolving understanding of growth regulation in human breast cancer: interactions of the steroid and peptide growth regulatory pathwaysCindy A Wilson
J Natl Cancer Inst 97:1238-9. 2005 - Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancerJennifer A Byrne
Molecular Oncology Laboratory, Oncology Research Unit, The University of Sydney Discipline of Paediatrics and Child Health, The Children s Hospital at Westmead, New South Wales, Australia
Int J Cancer 117:1049-54. 2005..TPD52 therefore represents a novel molecular marker in ovarian cancer, which is broadly expressed across the different histologic subtypes and whose upregulation frequently reflects increased TPD52 copy number... - Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancerJudith Hurley
Sylvester Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
J Clin Oncol 24:1831-8. 2006..To evaluate the efficacy and safety of docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2 (HER2) -positive, locally advanced breast cancer (LABC)... - Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancerMark D Pegram
Oncology Research Network, David Geffen School of Medicine, and Division of Hematology/Oncology, University of California, Los Angeles 90095-7077, USA
J Natl Cancer Inst 96:759-69. 2004..The BCIRG is conducting ongoing randomized studies of the three-drug combination in both the metastatic and adjuvant settings... - First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumorsPamela N Munster
Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
Clin Cancer Res 13:1238-45. 2007..To test the tolerability, safety, and recommended phase II dose of CP-724,714, a reversible, highly selective, oral HER2 tyrosine kinase inhibitor in patients with advanced solid tumor malignancies that express HER2... - Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumabLee W Jones
Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
Cancer Epidemiol Biomarkers Prev 16:1026-31. 2007..We measured 14 metabolic and vascular established cardiovascular disease (CVD) risk factors, body mass index, cardiorespiratory fitness, and left ventricular systolic function. All assessments were done within a 14-day period... - Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancerMark D Pegram
Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles 90095-7077, USA
J Natl Cancer Inst 96:739-49. 2004.... - Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progressionDebu Tripathy
University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 8852, USA
J Clin Oncol 22:1063-70. 2004..We conducted an extension study to this trial to obtain additional safety information and to provide trastuzumab following disease progression... - ERCC5 is a novel biomarker of ovarian cancer prognosisChristine S Walsh
Department of Obstetrics and Gynecology, Cedars Sinai Women s Cancer Research Institute, Samuel Oschin Comprehensive Cancer Institute, David Geffen School of Medicine, University of California at Los Angeles, CA 90048, USA
J Clin Oncol 26:2952-8. 2008..Gene expression analyses were performed through microarray experiments. Candidate genes were tested for independent effects on survival using Cox proportional hazards models, Kaplan-Meier survival curves, and the log-rank test... - Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?Gottfried E Konecny
J Natl Cancer Inst 95:1813-5. 2003 - Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumabRobert D Mass
Genentech, Inc, South San Francisco, CA 94080, USA
Clin Breast Cancer 6:240-6. 2005..CONCLUSION: These data indicate that assessment of HER2 amplification by FISH is the preferred method to select patients for trastuzumab therapy... - Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug developmentJohn W Park
University of California, San Francisco Cancer Center, San Francisco, California 94115-1710, USA
Clin Cancer Res 10:3885-96. 2004
Research Grants
- ACADEMIC TRAINING IN MEDICAL ONCOLOGYDennis Slamon; Fiscal Year: 2005..This application seeks support for the critical and pivotal 2-year period which transitions the trainee from his/her initial clinical oncology experience to a career in academic medical oncology. ..
- SIGNAL TRANSDUCTION IN ONCOGENESISDennis Slamon; Fiscal Year: 2006..We feel the likelihood of important findings in both basic and translational research results from these efforts is high. ..